The consequences of chronic kidney disease on bone metabolism and growth in children

Nephrology Dialysis Transplantation

Volumn 27, Issue 8, 2012, Pages 3063-3071

  Bacchetta, Justine ^a,b,c   Harambat, Jérôme ^d   Cochat, Pierre ^b   Salusky, Isidro B ^e   Wesseling Perry, Katherine ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bone; chronic kidney disease; growth; paediatrics; vascular calcifications

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM SALT; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PLACEBO; RECOMBINANT GROWTH HORMONE; SEVELAMER; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D STEROL;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DISEASE; BONE EXAMINATION; BONE LESION; BONE METABOLISM; CHILD; CHILD GROWTH; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; GROWTH DISORDER; GROWTH RETARDATION; HUMAN; KIDNEY TRANSPLANTATION; METABOLIC ACIDOSIS; METABOLIC BONE DISEASE; MINERAL METABOLISM; NONHUMAN; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM; SHORT STATURE; TREATMENT DURATION; TREATMENT RESPONSE;

BONE AND BONES; BONE DEVELOPMENT; CHILD; CHILD DEVELOPMENT; DEVELOPMENTAL DISABILITIES; GROWTH DISORDERS; HUMANS; MINERALS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VASCULAR DISEASES;

EID: 84864624787     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs299     Document Type: Article

References (102)

1. Leonard MB. A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol 2007; 22: 1815-1824.
2. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 2007; 18: 223-234.
3. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 2008; 23: 195-207.
4. Hruska KA, Choi ET, Memon I et al. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD- MBD). Pediatr Nephrol [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2010; 25: 769-778.
5. Groothoff JW, Offringa M, Van Eck-Smit BL et al. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int 2003; 63: 266-275.
6. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
7. Yamashita T, Konishi M, Miyake A et al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277: 28265-28270.
8. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol 2008; 23: 41-48.
9. Salusky IB, Goodman WG. Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Kidney Int 1995; 48: 657-665.
10. Guyton A, Hall J. Pituitary hormones and their control by the hypothalamus. In: Guyton A (ed). Textbook of Medical Physiology, 11th edn. Philadelphia: Elsevier Saunders, 2006, pp. 918-929.
11. Courtland HW, Sun H, Beth-On M et al. Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production. J Bone Miner Res [Research Support, N.I.H., Extramural] 2011; 26: 761-768.
12. Kuizon BD, Salusky IB. Growth retardation in children with chronic renal failure. J Bone Miner Res 1999; 14: 1680-1690.
13. Wesseling-Perry K, Pereira RC, Tseng CH et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 146-152.
14. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
15. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant 2008; 23: 2733-2737.
16. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int [Research Support, N.I.H., Extramural] 2011; 79: 1370-1378.
17. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585.
18. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol 2009; 296: F470-F476.
19. Prie D, Urena Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009; 75: 882-889.
20. Lafage-Proust MH. Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int 2010; 77: 390-392.
21. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238.
22. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77:211-218.
23. Heidbreder E, Naujoks H, Brosa U et al. The calcium-parathyroid hormone regulation in chronic renal failure investigation of its dynamic secretion pattern. Horm Metab Res 1997; 29: 70-75.
24. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
25. Priemel M, von Domarus C, Klatte TO et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2009; 25: 305-312.
26. Ritter CS, Brown AJ. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J Mol Endocrinol [In Vitro Research Support, Non-U.S. Gov't] 2011; 46: 63-66.
27. Shroff R, Wan M, Gullet A et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012:doi:10.2215/CJN.04760511.
28. Bacchetta J, Ranchin B, Dubourg L et al. Vitamin D revisited: a cornerstone of health? Arch Pediatr 2010; 17: 1687-1695.
29. NAPRTCS. Annual report, section dialysis 12-12005.
30. Vimalachandra D, Hodson EM, Willis NS et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2006; 3: CD003264.
31. Mahan JD, Warady BA, Frane J et al. First-year response to rhGH therapy in children with CKD: a National Cooperative Growth Study Report. Pediatr Nephrol 2010; 25: 1125-1130.
32. Harambat J, Cochat P. Growth after renal transplantation. Pediatr Nephrol [Review] 2009; 24: 1297-1306.
33. Mahan JD, Warady BA. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006; 21: 917-930.
34. Klaus G, Watson A, Edefonti A et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21: 151-159.
35. Tonshoff B, Cronin MJ, Reichert M et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Clin Endocrinol Metab 1997; 82: 1007-1013.
36. Tonshoff B, Blum WF, Mehls O. Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int Suppl 1997; 58: S106-S113.
37. Powell DR, Liu F, Baker BK et al. Insulin-like growth factorbinding protein-6 levels are elevated in serum of children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1997; 82: 2978-2984.
38. Powell DR, Durham SK, Liu F et al. The insulin-like growth factor axis and growth in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1998; 83: 1654-1661.
39. Bacchetta J, Boutroy S, Juillard L et al. Bone imaging and chronic kidney disease: will high-resolution peripheral tomography improve bone evaluation and therapeutic management? J Ren Nutr 2009; 19: 44-49.
40. Yamada S, Inaba M, Kurajoh M et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf) 2008; 69: 189-196.
41. Yang L, Grey V. Pediatric reference intervals for bone markers. Clin Biochem 2006; 39: 561-568.
42. Bianchi ML, Baim S, Bishop NJ et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 2010; 25: 37-47.
43. Weber LT, Mehls O. Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol 2010; 25: 3-5.
44. Soyka LA, Fairfield WP, Klibanski A. Clinical review 117: hormonal determinants and disorders of peak bone mass in children. J Clin Endocrinol Metab 2000; 85: 3951-3963.
45. Hernandez JD, Wesseling K, Pereira R et al. Technical approach to iliac crest biopsy. Clin J Am Soc Nephrol 2008; 3 (Suppl 3): S164-S169.
46. Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008; 3 (Suppl 3): S140-S150.
47. Wesseling-Perry K, Pereira RC, Tseng CH et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 146-152.
48. Salusky IB, Coburn JW, Brill J et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988; 33: 975-982.
49. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166.
50. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
51. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
52. Bakkaloglu S, Wesseling-Perry K, Pereira R et al. Values of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 2010: Epub, doi;10.2215/CJN.01330210.
53. Kuizon BD, Goodman WG, Juppner H et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998; 53: 205-211.
54. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int [Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2011; 79: 112-119.
55. Bacchetta J, Boutroy S, Vilayphiou N et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res 2010; 25: 849-857.
56. Boutroy S, Bouxsein ML, Munoz F et al. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2005; 90: 6508-6515.
57. Lespessailles E, Gadois C, Lemineur G et al. Bone texture analysis on direct digital radiographic images: precision study and relationship with bone mineral density at the os calcis. Calcif Tissue Int 2007; 80: 97-102.
58. Majumdar S. Magnetic resonance imaging for osteoporosis. Skeletal Radiol 2008; 37: 95-97.
59. Bachrach LK. Measuring bone mass in children: can we really do it? Horm Res 2006; 65 (Suppl 2): 11-16.
60. Bacchetta J, Fargue S, Boutroy S et al. Bone metabolism in oxalosis: a single-center study using new bone imaging techniques and biomarkers. Pediatr Nephrol 2010:doi 10.1007/s00467-010- 1453x.
61. Lima EM, Goodman WG, Kuizon BD et al. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrol 2003; 18: 554-559.
62. Wetzsteon RJ, Kalkwarf HJ, Shults J et al. Volumetric bone mineral density and bone structure in childhood chronic kidney disease. J Bone Miner Res [Research Support, N.I.H., Extramural]. 2011; 26: 2235-2244.
63. Terpstra AM, Kalkwarf HJ, Shults J et al. Bone density and cortical structure after pediatric renal transplantation. J Am Soc Nephrol 2012.
64. Bacchetta J, Boutroy S, Vilayphiou N et al. Bone assessment in children with chronic kidney disease: data from two new bone imaging techniques in a single-center pilot study. Pediatr Nephrol [Research Support, Non-U.S. Gov't]. 2011; 26: 587-595.
65. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130.
66. Waller SC, Ridout D, Cantor T et al. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int 2005; 67: 2338-2345.
67. London GM, Marchais SJ, Guerin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol [Research Support, Non-U.S. Gov't] 2008; 19: 1827-1835.
68. Schmitt CP, Mehls O. Mineral and bone disorders in children with chronic kidney disease. Nat Rev Nephrol 2011; 7: 624-634.
69. Rees L. What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence? Pediatr Nephrol 2008; 23: 179-184.
70. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int [Research Support, U.S. Gov't, P.H.S. Review] 1999; 56: 383-392.
71. Shroff RC, Donald AE, Hiorns MP et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol [Research Support, Non-U.S. Gov't] 2007; 18: 2996-3003.
72. Cansick J, Waller S, Ridout D et al. Growth and PTH in prepubertal children on long-term dialysis. Pediatr Nephrol 2007; 22: 1349-1354.
73. Geary DF, Hodson EM, Craig JC. Interventions for bone disease in children with chronic kidney disease. Cochrane Database Syst Rev 2010; CD008327.
74. Salusky IB, Goodman WG, Sahney S et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-2508.
75. Pieper AK, Haffner D, Hoppe B et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 2006; 47: 625-635.
76. Gonzalez E, Schomberg J, Amin N et al. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol 2010; 25: 373-375.
77. Salusky IB, Goodman WG. Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Kidney Int [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H. S. Review]. 1995; 48: 657-665.
78. Sanchez CP, Salusky IB, Kuizon BD et al. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1998; 54: 1879-1887.
79. Imel EA, DiMeglio LA, Hui SL et al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab [Clinical Trial Research Support, N.I.H., Extramural] 2010; 95: 1846-1850.
80. Serra AL, Braun SC, Starke A et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant [Research Support, Non-U.S. Gov't] 2008; 8: 803-810.
81. Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol [Comparative Study Research Support, N.I.H., Extramural Research Support, Non- U.S. Gov't] 2010; 298: F1315-F1322.
82. Muscheites J, Wigger M, Drueckler E et al. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 2008; 23: 1823-1829.
83. Bacchetta J, Plotton I, Ranchin B et al. Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism. Nephrol Dialysis, Transplant 2009; 24: 2595-2598.
84. Fine RN, Kohaut EC, Brown D et al. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebocontrolled study. Genentech Cooperative Study Group. J Pediatr 1994; 124: 374-382.
85. Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM et al. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 1991; 338: 585-590.
86. Haffner D, Schaefer F, Nissel R et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German study group for growth hormone treatment in chronic renal failure. N Engl J Med 2000; 343: 923-930.
87. K/DOQI Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46 (Suppl 1): 1-122.
88. Fine RN. Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective. Pediatr Nephrol 2010; 25: 725-732.
89. Krempien B, Mehls O, Ritz E. Morphological studies on pathogenesis of epiphyseal slipping in uremic children. Virchows Arch A Pathol Anat Histol 1974; 362: 129-143.
90. Seikaly MG, Salhab N, Warady BA et al. Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS. Pediatr Nephrol 2007; 22: 1195-1204.
91. Berard E, Andre JL, Guest G et al. Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephrology. Pediatr Nephrol 2008; 23: 2031-2038.
92. Tritos NA, Biller BM. Growth hormone and bone. Curr Opin Endocrinol Diabetes Obes 2009; 16: 415-422.
93. Sanchez CP, Goodman WG, Brandli D et al. Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids. J Bone Miner Res 1995; 10: 2-6.
94. Baroncelli GI, Bertelloni S, Sodini F et al. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab 2003; 16 (Suppl 2): 327-335.
95. Murray RD, Adams JE, Shalet SM. Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 2004; 89: 1586-1591.
96. Colao A, Di Somma C, Pivonello R et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84: 1919-1924.
97. Baum HB, Biller BM, Finkelstein JS et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 883-890.
98. Bacchetta J, Wesseling-Perry K, Kuizon B et al. The skeletal consequences of growth hormone therapy in children undergoing peritoneal dialysis. 2011 (submitted).
99. Greenbaum LA, Hidalgo G, Chand D et al. Obstacles to the prescribing of growth hormone in children with chronic kidney disease. Pediatr Nephrol 2008; 23: 1531-1535.
100. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis [Practice Guideline] 2009; 53 (3 Suppl 2): S11-S104.
101. Furth SL, Stablein D, Fine RN et al. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 2002; 109: 909-913.
102. Ibrahim S, Rashed L. Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Int Urol Nephrol 2009; 41: 163-169